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Behc ¸et’s disease (BD) is a multisystemic disease of unknown etiology characterized by chronic relapsing oral-genital ulcers and
uveitis.Multiplesystemicassociationsincludingarticular,gastrointestinal,cardiopulmonary,neurologic,andvascularinvolvement
are also observed in BD. Although the etiopathogenesis of the disease remains unknown, increased neutrophil functions such as
chemotaxis, phagocytosis, and excessive production of reactive oxygen species (ROS), including superoxide anion, which may
be responsible for oxidative tissue damage seen in BD, and also immunological alterations, T lymphocyte abnormalities in both
subpopulationandfunctionhavebeenconsideredtobecorrelatedwiththeetiopathogenesisofBD.Thereissomeclinicalevidence
suggesting that emotional stress and hormonal alterations can inﬂuence the course and disease activity of BD.
1.Introduction
Behc ¸et’s disease (BD) is a recurrent systemic inﬂammatory
disorder characterizedby four major symptoms consisting of
oral aphthous ulcers, ocular lesions, skin lesions, and genital
ulcerations. Although many studies have been conducted on
the etiopathogenesis of the disease, exact mechanisms have
not yet been fully understood [1]. Multiple systemic associa-
tions including articular, gastrointestinal, cardiopulmonary,
neurologic, and vascular involvement are also observed in
BD [1, 2]. Although the etiopathogenesis of the disease
remains unknown, increased neutrophil functions such
as chemotaxis, phagocytosis, and excessive production of
reactive oxygen species (ROS), including superoxide anion,
which may be responsible for oxidative tissue damage seen
in BD, and also immunological alterations, T lymphocyte
abnormalitiesinboth subpopulation andfunctionhavebeen
considered to be correlated with the etiopathogenesis of
BD. It was postulated that Behc ¸et’s disease is an autoim-
mune disease. Systemic manifestations such as articular,
gastrointestinal, and neurologic manifestations are not asso-
ciations with the disease. They are diﬀerent involvements
due to the disease [3, 4]. There is also some clinical
evidence suggesting that emotional stress and hormonal
alterationscaninﬂuencethecourseanddiseaseactivityofBD
[5–7].
2. Immune SystemDysregulations
The immunopathogenesis that is currently postulated is
shown in Figure 1. Primarily, hypersensitivity of T cells (αβT
cells and γδ-T cells) to multiple antigens appears to play a
critical role in the pathogenesis. The activation of mono-
cytes subsequent to T-cell activation through CD40–CD154
interactions as well as a variety of T-cell-derived cytokines
(IFN-γ and TNF-α) may result in the production of IL-12,
which leads to the shift to Th1 responses. In consequence
of abnormal T-cell activation, neutrophil activation may be
triggeredbycytokinessuchasIL-8,IL-17,IFN-γ,andTNF-α.
Whereas the roles of costimulation molecules have not been
fullyexploredinBehc ¸et’sdisease,thepresenceofanti-CTLA-
4 antibody has been reported in a fraction of Behc ¸et’s disease
patients. Although the presence of this antibody might be
possibly involved in abnormal T-cell responses, the antibody
might be produced only as a secondary phenomenon of
recurrent T-cell activation in Behc ¸et’s disease [7, 8].
3.CellularandHumoralImmunology
Although cellular activity is increased in the peripheral
blood of BD patients, reports of neonatal BD cases in
the children of aﬀected women also suggest a role for
humoral factors. Indeed, various cytokine proﬁles and2 Pathology Research International
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Figure 1: Proposed model of the pathogenesis in Behc ¸et’s disease. Ag: antigen; APC: antigen-presenting cells; HSP: heat shock protein;
IFN: interferon; IL: interleukin; IPP: isoprenyl pyrophosphate; PPP: prenyl pyrophosphate; TCR: T-cell receptor; Th1: T-helper cells type 1;
TNF-α: tumor necrosis factor α.
elevated lymphocyte populations have been demonstrated
in BD with an imbalance between Th1- and Th2-phenotype
lymphocyte components of the immune response. However,
as T lymphocytes are particularly responsive to antigens of
viral or bacterial pathogens, the skew is therefore suggested
toward Th1-phenotype lymphocyte response followed by an
inﬁltration into the aﬀected regions [7, 8].
3.1. Th1-Phenotype Lymphocytes. Th1-phenotype lympho-
cytes that produce proinﬂammatory mediators called
cytokines, such as IL-2, IL-6, IL-8, IL-12, IL-18, TNF-α,a n d
IFN-γ are increased in patients with BD [7].
3.2. Th2-Phenotype Lymphocytes. Th2 cytokines have
responses precisely opposite to those of reactions elicited by
Th1. The results regarding the Th2-phenotype lymphocytes
and cytokines are controversial. Some studies have shown
decreased levels of CD8 T lymphocytes, IL-4, and IL-
10, whereas some others demonstrated increased CD8
T-lymphocyte populations as well as increased serum
concentrations of IL-4, IL-6, IL-10, and IL-13, indicating a
reduced circulating CD4/CD8 ratio [7].
3.3.Immunoglobulins, ImmuneComplexes, andAnticardiolip-
ins. Enhanced cell-mediated cytotoxicity with demonstrated
circulating immune complex response (usually antigen-
antibody complexes) against oral mucosal antigens, espe-
cially during an exacerbation period, supports the presence
of both Th1 and Th2 types of immune reaction in BD. These
immune complexes may be priming factors that trigger the
disease with a recruitment of some immune cells to the site
of inﬂammation that are present in the sera of more than
one-half of BD patients [7].
3.4. Neutrophils, Monocytes, and Complements. There is a
generalized derangement of the lymphocyte and neutrophil
populations during the course of BD, which is characterized
by elevated peripheral white blood cell count, activated
monocytes, increased neutrophil motility with inﬁltration
into the cutaneous and ocular lesions, and increased circu-
lating proteins such as C3, C4, C5, IgA, Haptoglobin, and
orosomucoid [9]. Active monocytes produce a number of
proinﬂammatory cytokines, such as IL-1, IL-6, IL-8, TNF-
α, and granulocyte-macrophage colony stimulating factor
(GM-CSF), and these cytokines contribute to neutrophil
activation by their augmented interactions with endothelial
cells, causing tissue damage possibly by priming neutrophils
[10]. Indeed, various hyperfunctions of neutrophils in
peripheral blood such as chemotaxis, active oxygen produc-
tion, and phagocytosis with inﬁltration into the lesion sites
have all been implicated during the course of active BD [11].
Moreover, leukocyte adhesion molecules such as P and L
selectins,Mac-1,andCD4areexpressedonperipheralleuko-
cytes and participate in the cascade of leukocyte chemotaxis
and adhesion, indicating the presence of immune system
activation in BD [12]. Plasma myeloperoxidase (MPO)
activity, representing neutrophil activation, and biomarkers
of oxidative stress reﬂecting protein oxidation, such as the
levels of advanced oxidation protein products (AOPPs), have
beenfoundtobeincreasedinBDpatients,especiallyinactive
disease [13]. This suggests again the activated neutrophils in
the etiopathogenesis of BD.
3.5. Heat Shock Proteins in BD. Heat shock protein (HSP)
is a small, ubiquitous stress-related streptococcal antigen
that can be induced by infections, trauma, heat, UV-B,
hypoxia, cold, and cytotoxic prostaglandins [14]. Anti-HSP-
65 antibodies cross-reactive with oral mucosal homogenates
a n do r a ls t r e p t o c o c c ih a v eb e e nr e p o r t e di nB D .T - c e l l
antigen receptor (TCR) γδ-T lymphocytes are important in
ﬁrst-line defense that allows T cells to recognize a wide range
of antigens as well as in regulation of Th1-Th2 responses,Pathology Research International 3
and HSP itself activates these subsets of cells known as the
CD4 and γδ-T lymphocytes that do not require peptide-
MHC I or II association for stimulation. Likewise, microbial
HSP-65-derived peptides and their mammalian counterpart
HSP-60, both of which cause autoimmunity with 60%
of sequence homology, have recently been demonstrated
to stimulate lymphoproliferative response in BD patients
[14, 15].
Recent developments in the innate immune system with
the description of toll-like receptors (TLRs) and HSP-60 as a
ligand for TLR-2 and TLR-4 suggest also the role of HSP-60
asanendogenous“danger”signaltotheimmunesystemwith
rapid inﬂammatory cytokine release and the enhancement
ofadaptiveTh1-typeresponses[16].Althoughcontradictory
results have been reported for peripheral blood TCR γδ-
T lymphocyte counts, HSPs have pathophysiologically been
suggested in BD because increased T- and B-cell responses
against these autoantigens are observed in diﬀerent ethnic
populations in BD [17] .T h e r e f o r e ,t h e s ec e l l sa sw e l la s
HSPs may participate during the course of ocular and
mucocutaneous BD because of the following: (1) antibodies
against bacterial or human HSP-60/65 are capable of cross-
reacting with retinal antigens; (2) exposure to exogenous or
endogenous HSPs results in the proliferation of peripheral T
lymphocytes of ocular BD patients directed against both the
target and retinal antigens; (3) lesional skin of BD contains
increased numbers of both HSP-60 and TCR γδ-T lympho-
cytes; (4) γδ-T lymphocyte is present in tissue specimens
whereas HSP-65 expression is abundantly upregulated in
epidermal regions of active skin lesions such as erythema
nodosum and mucocutaneous lesions of patients with BD;
ﬁnally (5) elevated HSPs upregulate the expression of the
MICA locus in BD patients lying adjacent to the HLA-B5101
locus [18, 19]. Moreover, increased TCR-γδ-T lymphocytes
is normally cultured from inﬂamed vitreous and have been
detected in cerebrospinal ﬂuid (CSF) and bronchoalveolar
lavage of patients with active BD. Furthermore, subcuta-
neous inoculation or oral administration of HSP-derived
peptide induces experimental uveitis [20]. Taken together,
BD seems to result from heightened responsiveness to
bacterial antigens in genetically susceptible hosts. In other
words, streptococcal HSP epitopes may reach the submucosa
of the mouth ulcers and elicit an inﬂammatory reaction
through upregulated HSP expression by minor injuries,
which stimulate self-HSP-60 reactive clones, suggesting
diﬀerent local HSP responsive T-lymphocyte repertoire from
that of peripheral blood. This, in turn, may serve as a local
antigen with augmentation of inﬂammatory reaction.
3.6. Oxidative Stress, Antioxidative Defense, and Trace Ele-
ments in BD. In spite of unknown aetiology, it is now
accepted that reactive oxygen species produced by neu-
trophils may be related to the pathogenesis of BD. Not
only increased malondialdehyde and superoxide dismutase
levels but also decreased glutathione peroxidase activities in
erythrocytes were observed in patients with BD [21]. Toxic
compounds such as pesticides and insecticides have been
incriminated in BD. Recently, Aynacioglu et al. showed that
N-acetyltransferase2∗5Ballelewasslightlyhigherinpatients
with BD. This enzyme contributes to drug and toxic com-
pound metabolism [22]. Excessive superoxide anion (O2
−)
production and raised ADA activity (a marker of activated
neutrophil function, chemotaxis, and phagocytosis), as well
as hydrogen peroxide- (H2O2-) induced hydroxyl radical
(OH) and malondialdehyde productions have been demon-
strated in BD patients, suggesting neutrophil-mediated
immunity and increased amount of reactive oxygen species
(ROS) production, especially in the exacerbation period
[23]. Indeed, neutrophils of active BD patients are much
more vulnerable to oxidative injury than those from inactive
patients. On the other hand, endogenous free radical scav-
enging enzymes, such as superoxide dismutase, glutathione
peroxidase, and catalase, have been found to be decreased
in patients with BD [24]. This clearly results in insuﬃcient
disposal of O2
− and H2O2 and, therefore, limited enzymatic
adaptation to ROS with circulating prooxidants in such
patients [25]. As activated T lymphocytes cause neutrophil
hyperfunction with overproduction of NO, O2
−,H 2O2,O H ,
a n ds i n gl e to x y g e n( 1O2) that is one of main ROS-generation
system in BD patients, the increased production of ADA
and LPO system conﬁrms aggravated lymphocyte function
and ROS production, suggesting a possible new and simple
biochemical activity marker for ADA in BD. Therefore, the
interplay between ADA, O2
−, NO, and peroxynitrite anion in
the vascular wall of BD patients is likely to cause antioxidant
enzyme depletion, oxidative LPO and, therefore, deterio-
rated oxidant/antioxidant equilibrium, creating a condition
known as oxidative stress [26] .T r a c ee l e m e n t sf u n c t i o n
as cofactors to antioxidant enzymes. Erythrocyte selenium,
plasma iron, manganese, and zinc levels are decreased,
whereas plasma copper, erythrocyte zinc, and manganese
levels are elevated in patients with BD. In addition, the
plasma concentrations of powerful nonenzymatic antioxi-
dants such as vitamins A, C, E, and β-carotene are lower in
such patients [27, 28].
3.7. Endothelial Cells, Nitric Oxide, and Related New Inﬂam-
matory Molecules. Behc ¸et disease is characterized by vas-
culitis and endothelial cell dysfunction. Nitric oxide (NO),
endothelium-derived relaxing factor, is a free oxygen radical
that is produced by endothelial cells upon stimulation by
immunologic, infectious, and inﬂammatory stimuli, such as
cytokines, INF-γ, lipopolysaccharides, and endotoxin [29].
It is an important mediator of uveal inﬂammation, and
NO synthase activity has experimentally been demonstrated
in the uveal tissue [30]. Recently, evidence is accumulating
for the role of NO during the course of BD. Serum
nitrite and nitrate concentrations as an indicator of recent
NO production have been found to be decreased in BD
patients [31], and three recent studies have shown that Glu-
Asp298 polymorphisms of endothelial NO synthase gene
are associated with BD susceptibility [32]. In another study,
serum, erythrocyte, and synovial NO have been demon-
strated in BD [33]. NO concentrations are increased in BD
patients and associated with disease activity. Similar results
have been obtained by various investigators supporting this
ﬁnding [34]. In addition, aqueous humor NO levels have
been reported to be increased in uveitic BD patients [35].4 Pathology Research International
Increased serum levels of NO may be explained by various
molecules that have recently been implicated during the
course of BD. First, homocysteine, which is found to be
elevatedin BD [36], enhances NO synthesis from endothelial
cells, induces the expression of chemoattractants by oxygen
free radicals, and is the potent inducer for IL-6, IL-8, and
TNF-α [37]. Because increased levels of proinﬂammatory
cytokines by endothelial cells, neutrophils, and macrophages
have well been established during the course of BD [38],
homocysteine- and cytokine-induced overproduction of NO
by immunocompetent cells may pathophysiologically be
related with BD and uveitis due to NO-generating cells
such as the endothelium, neutrophils, and macrophages,
resulting in oxidative stress with self-propagating LPO
in such patients [39]. Elevated NO levels, in turn, may
compensate these eﬀects of homocysteine by its adhesion-
inhibitory properties. Second, another endothelium-speciﬁc
cytokine, vascular endothelial growth factor, is produced
by macrophages, activated human neutrophils, monocytes,
and vascular endothelial cells and potently stimulates angio-
genesis, endothelium-dependent vasodilatation, and NO
production by its receptors located on the systemic and
retinal vascular endothelial cells [40]. Indeed, inﬂammation
and proinﬂammatory cytokines induce VEGF expression
and VEGF itself upregulates NO synthase expression in
endothelial cells, inducing large amount of NO production
and leukocyte mobilization [41]. Because serum VEGF
levels have been found to be increased in BD patients and
correlatedwithoculardiseasewithdemonstratedVEGFgene
polymorphisms [42], VEGF may therefore have contributed
to the elevated NO levels along with an additional risk factor
for the development of retinal vaso-occlusive disease and
neovascularization, resulting in poor visual outcome in such
patients. Finally, leptin, a product of the recently cloned ob
gene, is expressed in human vasculature and endothelial cells
and plays a crucial role during inﬂammation, and impaired
endothelial function reverses after leptin replacement [43].
TNF increases serum leptin levels in human, and leptin itself
directly enhances the release of NO from endothelial cells,
suggesting an autocrine or paracrine modulator role [44].
Because serum leptin levels have been demonstrated to be
h i g h e ri na c u t e - p h a s er e s p o n s ea sw e l la si nB Dp a t i e n t s
[45], the pathophysiological signiﬁcance of homocysteine-
cytokine-VEGF-leptin-NO cascade should further be inves-
tigated in detail during the course of BD.
4.TheRole of StressFactorsand
Stress Hormones in BD
4.1. Hypothalamo-Pituitary Adrenal Axis in Behc ¸et’s Disease.
Dysfunction of the hypophysis gland in both humans and
animalswasshowntobeassociatedwithseveralautoimmune
diseases [46, 47]. As in other chronic autoimmune diseases,
there may be some changes in cortisol levels due to adrenal
tiredness associated with long-term stress in Behc ¸et’s disease.
Colak et al. observed that cortisol values in the 60th minute
were signiﬁcantly lower in Behc ¸et’s disease patients than
in the control group after 1μg ACTH stimulation test.
In this study, when peak cortisol responses to low-dose
test were compared between patient and control groups, a
signiﬁcant decrease was found in the patient group. When
peak cortisol responses to low-dose test and standard-dose
test were compared in the patient group, peak cortisol
responses to low-dose test were found signiﬁcantly lower
than those to standard-dose test. Comparison of under the
curve cortisol responses between patient and control groups
showed that under the curve value was signiﬁcantly lower
between 30th and 60th minutes in low-dose test in the
patient group than in the control group. When percentage
increase values of cortisol responses to low-dose test were
compared between patient and control groups, the 60th
minute value in the patient group was found signiﬁcantly
lower than that in the control group [48]. Autoimmune
diseases develop when endocrine changes caused by various
stresses like infection, together with some regulatory defects,
aﬀect autoreactive cells and exceed the critical threshold that
leads to autoimmunity [49]. The most common cause of
primaryadrenalcortexfailureisautoimmuneadrenalitisthat
results in bilateral adrenal atrophy. Clinical signs of adrenal
failure are not seen until at least 90% of the adrenocortical
tissue is destroyed. The rate of the copresence of diseases
having autoimmune events in their pathogenesis is high.
Primary adrenal failure, which is an autoimmune disease,
may accompany Behc ¸et’s disease, for the aetiopathogenesis
of which autoimmunity is held responsible [50]. There
are some studies assessing adrenal functions in the other
autoimmune diseases including rheumatoid arthritis, sys-
temiclupuserythematosus,andSj¨ ogren’ssyndrome[51–55].
There is a partial dysfunction that can be revealed by LDT
in Behc ¸et’s syndrome patients [48]. It was concluded that
hypothalamo-pituitary adrenal axis was partially suppressed
in Behc ¸et’s disease and that occult adrenal failure should be
carefully considered in case of acute stress.
4.2. Sex Hormones in BD. While this paper has focused
on the HPA axis and glucocorticoids and their role in
susceptibility to inﬂammatory disease, estrogen is known to
playanextremelyimportantroleinimmunemodulationand
contributes to the approximately two- to tenfold higher ratio
of most autoimmune diseases in females of all species [56].
Ovariectomy has been shown to reduce, while replacement
of estrogen reconstitutes, this diﬀerential susceptibility to
experimental inﬂammatory arthritis in rodents [57]. Fur-
thermore,gender,menstrualcycle,andestrogenreplacement
therapy have all been shown to aﬀect HPA axis and immune
function in human studies [58].
4.3. Activation of Neutrophils by Testosterone in Behc ¸et’s
Disease. To determine the putative role of testosterone on
neutrophil activity exhibited by patients with BD, peripheral
blood neutrophils were examined in vitro before and after
treatment with testosterone. Yavuz et al. analysed peripheral
blood neutrophils of 49 patients with BD, 33 patients with
ankylosing spondylitis, 8 female patients with hirsutism, and
31healthyindividuals.Theyindicatedthatgenderdiﬀerences
were striking not only in the mean oxidative burst response
butalsointherateofapoptosis.MaleBDpatientsmanifestedPathology Research International 5
increased burst response before testosterone treatment com-
pared with females. Consistent with oxidative burst results,
baseline percentages of CD66b- and CD16-expressing cells
weregreaterinmaleBDpatients.Adecreasedapoptosis ratio
was observed using PhiPhilux and PI staining in BD patients.
This was especially signiﬁcant in male compared to female
BD patients. BD itself rather than the gender was found to be
the most important predictor of this altered apoptosis ratio
in BD determined by linear regression analysis [59]. These
results suggested that a contribution of testosterone to the
BD pathogenesis could not be ruled out.
4.4. Prolactin (PRL) and Other Sex Hormones in BD. Pro-
lactin acts as a neuroendocrine modulator of both skin
epithelial growth and the skin immune system. Moreover,
it was proposed that PRL forms a “PRL circuit” between
the skin and the central nervous system [60]. This concept
can now be readily integrated into current views on the
multilevel neuroendocrine-immune communication along
the “brain-skin axis” in health and disease [61]. Inspired by
this hypothesis, PRL and PRL-receptors expression have now
been demonstrated in several cutaneous cell populations,
including keratinocytes, ﬁbroblasts, sweat glands, and seba-
ceousglands.Inaddition,PRLandPRL-receptorsexpression
has also been identiﬁed in the key cellular protagonists of the
skin immune system [62].
The results regarding the PRL levels in BD are contro-
versial. Some studies have shown increased levels of PRL,
whereas some others demonstrated decreased and normal
levelsofPRLinBD[63–66].Karakusetal.indicatedthatPRL
levels of male patients having ocular involvement had lower
levels of inactive group, while female patients having ocular
involvement had lower levels of DHEA-S compared to the
activegroup.Theyfoundthatnootherremarkablehormonal
diﬀerence including FSH, LH, T3, T4, TSH was observed
amongBehc ¸et’spatients[67].G¨ uletal.foundthatmeantotal
testosterone levels of BD patients were signiﬁcantly lower
thanthoseofhealthycontrols;however,patientswithBDand
increased 17-OH-progesteron levels only had normal total
testosterone levels. And they also indicated more commonly
21-hydroxylase gene mutations and deﬁciency in BD [68].
Mat et al. found that androgen receptor density in scrotal
skin of BD was normal [69]. In some studies, it has been
suggested that there is a correlation between high serum pro-
lactin levels and activation of certain autoimmune diseases.
Hyperprolactinemia, which has the potential to exacerbate
autoimmunity, may coexist with BD [70]. For many years,
bromocriptine, a D1 and D2 dopamine receptor agonist, has
been the standard medicine for hyperprolactinemic patients.
That there was a beneﬁcial eﬀect of low-dose cyclosporine
plus bromocriptine combination therapy on autoimmune
human uveitis may indicate the role of prolactin in the
pathogenesis of BD [70].
4.5. Neuropeptides in Behc ¸et’s Disease. Recently, the associa-
tion between stressful life events and various dermatologic
diseases is explained by the concept of neuro-immune-
cutaneous system [71]. It was reported that neuropeptides,
especially substance P (SP) and calcitonin-gene-related
peptide (CGRP), and neurotrophins such as nerve growth
factor (NGF) aﬀect the pathogenesis of skin disorders like
atopic dermatitis and psoriasis vulgaris [72, 73]. Taking into
account inﬂammatory responses that occur during emo-
tional stress in BD patients, it seems likely that neurogenic
mediators may be associated with BD. Jang et al. observed
that strong immunoreactivity of SP and NGF was seen in
the epidermis, panniculitis lesion, and vasculitis lesion of
BD patients. However, CGRP levels were decreased in BD
patients [74]. Aki et al. noted that SP in the active BD
period was signiﬁcantly higher than controls whereas that
of inactive BD was not. SP in active BD was signiﬁcantly
higher than in inactive BD. And also they found that
CGRP during both active and inactive periods of BD was
signiﬁcantly higher than controls, and CGRP in active BD
was signiﬁcantly higher than in inactive BD. They think
that the increased SP and CGRP found in active BD may
be associated with BD pathogenesis through the increase
in expression of cellular adhesion molecules, IL-8 release,
and neutrophil chemotaxis [75]. Endothelial cells have
speciﬁc receptors for SP and CGRP. These neuropeptides
inﬂuence endothelial cell functions through their receptors.
SP and CGRP have several eﬀects that can play a role
in the pathogenesis of vasculitis, via endothelial cells and
neutrophils. The aforementioned eﬀects of SP and CGRP
on vasodilatation, vascular permeability, and endothelial-
associated inﬂammation suggest that they may have a role in
vasculitic events [76]. In conclusion, an increase in serum SP
a n dC G R Pl e v e l si nB Dw a sf o u n di nd i ﬀerent studies. This
suggests that the neuropeptides may be contributing to BD
pathogenesis by aﬀecting vasculitic events.
4.6. Natriuretic Peptides in Behc ¸et’s Disease. Natriuretic
peptides (NPs) maintain an important endocrine-paracrine
inﬂuence over many vascular parameters. NPs have a
fundamental role in cardiovascular remodeling, volume
homeostasis,andtheresponsetoischemia.Moreover,theNP
level is associated with cardiac problems such as heart failure
andthromboembolism[77,78].Cardiovascularinvolvement
in BD includes coronary arteritis, coronary artery aneurysm,
myocarditis, pericarditis, acute myocardial infarction, silent
myocardial ischemia, intracardiac thrombus, heart failure,
vasculitis, venous occlusions, arterial aneurysms, and/or
arterial occlusions [79]. Yaˇ gci et al. studied serum atrial
natriuretic peptide (ANP), brain natriuretic peptide (BNP),
and C-type natriuretic peptide (CNP) levels in Behc ¸et’s
patients with active and inactive period. Serum ANP con-
centrations of the BD patients in the active subgroup were
signiﬁcantly lower than those of the healthy controls. In this
study, when compared with healthy controls, serum BNP
levels were found to be signiﬁcantly higher in both the active
and inactive BD subgroups. When the study groups were
evaluated on the basis of CNP levels, the active BD subgroup
had signiﬁcantly decreased CNP levels in comparison with
the inactive and control groups [80]. ANP has been linked
to the immune system, and it regulates the balance between
TH1 and TH2 responses [81–83]. It may be supposed that
decreased CNP levels in the patients may be one of the
consequences of the endothelial dysfunction in BD.6 Pathology Research International
Table 1: Key stress protagonists in the BD.
Stress mediators, hormones, and
cells Main biological eﬀect In BD
Hormones of the HPA axis (CRH,
ACTH, glucocorticoids)
Activate mast cells
UpregulateproductionofIL-4,IL-6,IL-10,andIL-
13
InhibittheproductionofIL-12,IFN-γ,andTNF-α
by antigen-presenting cells and T-helper 1 cells
Partial HPA axis dysfunction [10].
Prolactin
Participates in early and late T-cell activating
events; contributes to a proinﬂammatory and
apoptosis-prone environment
Increased, decreased, or normal [26–29].
Sex hormones Immune modulation, aﬀect HPA axis
Activation of neutrophils by testosterone, lower
levels of DHEA-S (ocular BD), increased 17-OH-
progesteron, testosterone, estradiol, FSH, LH,
T 3 ,T 4 ,a n dn o r m a lT S Hl e v e l sa n da n d r o g e n
receptor density in scrotal skin, increased 21-
hydroxylase gene mutations [30–32].
Substance P
Induces inﬂammation
Induces lymphocyte proliferation
Activates mast cells
Higher levels in active BD, strong immunoreac-
tivity of SP in vasculitic skin lesions [39, 45].
CGRP
Inhibits proliferation and IL-2 release of
T lymphocytes under immune challenges
Activates mast cells, induces vascular permeability
Increased or decreased levels in BD [45, 52].
NGF, NEP, neuropeptide degrad-
ing enzyme
Promotes “crosstalk” between neuronal and
immune cells
Acts as autocrine and paracrine factor in the
development and regulation of immune cells
Promotes monocyte and macrophage migration
through vascular endothelium
Activates mast cells
Strong immunoreactivity in vasculitic skin
lesions,
Decreased NGF levels in inactive BD
(Ocular-BD) [39, 52].
Natriuretic peptides
Endocrine-paracrineinﬂuenceovermanyvascular
parametersincludingﬂuidandelectrolytebalance,
vasodilatation, smooth muscle proliferation, and
the reactivity of immune cells.
Lower ANP concentrations in active BD, higher
serum BNP levels in BD, decreased CNP levels in
active BD [56].
Heat shock proteins Activates CD4 and γδ-T lymphocytes
Antibodies against bacterial or human HSP-
60/65 are capable of cross-reacting with retinal
antigens
Exposure to HSPs results in the proliferation of
peripheral T lymphocytes of ocular BD patients
Lesional skin of BD contains increased numbers
of both HSP-60 and TCR γδ-T lymphocytes
γδ-T lymphocyte is present in tissue specimens,
whereas HSP-65 expression is abundantly upreg-
ulated in epidermal regions of active skin lesions
Elevated HSPs upregulate the expression of the
MICA locus in BD patients [68, 69].
Oxidative stress Activate neutrophil function, chemotaxis, and
phagocytosis
Excessive superoxide anion production, raised
ADA activity, hydrogen peroxide-induced
hydroxyl radical, and malondialdehyde
productions [71, 75]
Antioxidative defense Free radical scavenging Decreased superoxide dismutase, glutathione
peroxidase, and catalase levels [71].
Trace elements and vitamins Cofactors to antioxidant enzymes
Nonenzymatic antioxidants
Decreased erythrocyte selenium, plasma iron,
manganese, and zinc levels, increased plasma
copper, erythrocyte zinc, and manganese levels,
lower plasma concentrations of vitamins A, C, E,
and β-carotene [77, 78].Pathology Research International 7
Table 1: Continued.
Stress mediators, hormones, and
cells Main biological eﬀect In BD
Neutrophils, monocytes,
and complements
Produce a number of proinﬂammatory cytokines,
chemotaxis, active oxygen production, and phago-
cytosis
Innate immune system activation
Hyperfunctions of neutrophils, leukocyte adhe-
sion molecules including P and L selectins, Mac-
1 and CD4 expression on peripheral leukocytes,
increased plasma myeloperoxidase activity, ele-
vatedperipheralwhitebloodcellcount,activated
monocytes, increased neutrophil motility, and
circulating proteins including C3, C4, C5 [79].
Nitric oxide Free oxygen radical
Decreased serum nitrite and nitrate
concentrations, and Glu-Asp298polymorphisms
of endothelial NO synthase gene, increased NO
concentration [85–90].
Psychological factors Regulatetheimmunesystematregional,local,and
systemic levels
More depression and anxiety scores, aﬀected
quality of life [85–88].
4.7. Stress Management in BD. The interaction between the
physical and psychological factors seems reasonable in the
experience of a BD. Numerous studies have provided a
strong basis for considering the role of psychosocial factors
on the course the rheumatic disease. Gur et al. established
that arthropathy was one of the common manifestations
of BD. Arthritis in BD aﬀects considerably patients’ pain
levels and quality of life [84]. Koc ¸ak et al. conclude that
depressive mood according to the BDI scale correlates with
the sexual status of BD patients, and this may be because
of the depressive eﬀect of BD as a chronic disease [85].
Taner et al. observed that patients with BH had more
depression and anxiety scores than in psoriatic patients
[86]. U˘ guz et al. observed that concurrent major depression
had a negative impact on quality of life of BD patients
and that quality of life was negatively correlated with the
severity of depressive symptoms. Behc ¸et’s disease was a
multisystemic inﬂammatory disorder associated with high
levels of depressive symptoms and lower quality of life [87].
Psychological/psychiatric interventions could usefully be
included in the normal Behc ¸et’s patients assessment, as it
shouldbothimprovepatientcareandbecosteﬀective.Coun-
seling and psychotropic medications can beneﬁt patients
with depression or anxiety related to their skin problems,
and consultation with a dermatologist and, in some cases,
a psychiatrist can be beneﬁcial. The eﬀect of skin diseases is
considerable and underappreciated. Physicians applying the
biopsychosocial model to skin diseases will be rewarded with
improved therapeutic alliances and with grateful patients
who experience improved quality of life [88].
No speciﬁc pharmacological interventions are as yet
available to prevent or treat stress triggered skin disorders
in humans. However, based on the wealth of data that
has recently accumulated in this ﬁeld, reasonable pharma-
cological treatment options are slowly coming into sight.
Abrogation of mast-cell activation seems to be a promising
approach in this endeavor, but, to date, few if any clinically
available molecules can eﬀectively inhibit mast-cell activa-
tion. Disodium cromoglycate was shown to inhibit rodent
mast cells but was a very weak inhibitor of mast-cell cytokine
release [89]. Increasing recent evidence indicates that certain
ﬂavonols, such as quercetin, are powerful inhibitors of both
prestored and newly synthesized mediators from human
mast cells [90]. The combination of such ﬂavonoids with
proteoglycans, such as chondroitin sulphate, appears to
provide synergistic eﬃcacy by inhibiting both activation and
secretion of mast cells [91]. Appropriate CRH-R antagonists,
when available, might also provide a unique therapeutic
approach in skin conditions precipitated or worsened by
stress [92]. Further, the prototypic stress-associated neu-
ropeptide SP may be blocked by the application of a
high-aﬃnity neurokinin-1 receptor antagonist [93]. Thus,
neurokinin-1 receptor antagonists might be useful in allevi-
ating stress-induced hair loss and skin inﬂammation. NGF
receptor p75 antagonists also deserve systematic exploration
as candidate “antistress” drugs in the treatment of stress-
triggered or stress-aggravated skin disorders, such as psori-
asis and stress-induced telogen eﬄuvium [94]. However, one
evidently must be very cautious in translating results from
murine models to humans. No speciﬁc pharmacological
intervention—other than antidepressants and anxiolytics—
is currently clinically available to manage selectively the
impact of psychological stress on skin disorders in humans.
However, reasonable pharmacological treatment options are
coming into sight. Mast cells could be prominent targets
of CRH and related peptides, contributing to neurogenic
inﬂammation; it is therefore reasonable to propose the use
of CRHR antagonists. CRHR antagonists (e.g., antalarmin
or astressin) would be one class of molecules that could
be tested by local administration in the model systems
described, especially because higher CRHR-1 gene expres-
sion was documented in contact dermatitis [94]. Folates
supplementation may be useful for BD patients with hyper-
homocysteinemia. And also nonenzymatic antioxidants such
as vitamins A, C, E, and carotene, trace elements including
selenium, plasma iron, manganese, and zinc might be useful
in patients with BD, if they are low [78] (see Table 1).
5. Conclusion
However, an adaptive immune system is also crucial in BD,
with possibly both external (streptococcal, superantigens)8 Pathology Research International
and internal (heat-shock- or organ-speciﬁc proteins) anti-
gens driving the pathogenic tissue T-cell inﬁltrations. Better
characterisation of pathogenic immune cell subsets, systemic
andlocalantigens,andabnormalcell-activationmechanisms
m a yh e l pi nt h ef u t u r et od e v e l o pm o r es p e c i ﬁ ca n dl e s st o x i c
immunotherapeutic approaches to the still unsatisfactorily
treated BD. There is some clinical evidence suggesting
that hormonal alterations can inﬂuence the course and
disease activity of BD. Behc ¸et’s experts should become far
more attentive to the eﬀect of psychological stress on skin
disorders, not only for the beneﬁt of their patients but also
because the skin serves as a very clinically relevant model
system for exploring the neuroimmunology of peripheral
and central stress responses.
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